



# HHS Public Access

## Author manuscript

*J Acquir Immune Defic Syndr.* Author manuscript; available in PMC 2018 September 01.

Published in final edited form as:

*J Acquir Immune Defic Syndr.* 2017 September 01; 76(1): e15–e18. doi:10.1097/QAI.0000000000001390.

## Predictors of retention in HIV care among youth (15–24) in a universal test-and-treat setting in rural Kenya

**Lillian B Brown<sup>1,2</sup>, James Ayieko<sup>3</sup>, Florence Mwangwa<sup>4</sup>, Asiphas Owaraganise<sup>4</sup>, Dalsone Kwarisiima<sup>4,6</sup>, Vivek Jain<sup>1</sup>, Theodore Ruel<sup>5</sup>, Tamara Clark<sup>1</sup>, Douglas Black<sup>1</sup>, Gabriel Chamie<sup>1</sup>, Elizabeth A Bukusi<sup>3</sup>, Craig R Cohen<sup>7</sup>, Moses R Kamya<sup>4,8</sup>, Maya L Petersen<sup>9</sup>, Edwin D Charlebois<sup>2</sup>, and Diane V Havlir<sup>1</sup>**

<sup>1</sup>University of California San Francisco, Division of HIV, ID and Global Medicine

<sup>2</sup>University of California San Francisco, Center for AIDS Prevention Studies

<sup>3</sup>Kenya Medical Research Institute

<sup>4</sup>Infectious Diseases Research Collaboration

<sup>5</sup>University of California San Francisco, Department of Pediatrics, Division of Infectious Diseases

<sup>6</sup>Makerere University Joint AIDS Program, Division of HIV Prevention

<sup>7</sup>University of California San Francisco, Bixby Center for Global Reproductive Health, Department of Obstetrics, Gynecology & Reproductive Sciences

<sup>8</sup>Makerere University College of Health Sciences, School of Medicine

<sup>9</sup>University of California Berkeley, Division of Biostatistics and Epidemiology

### Keywords

HIV/AIDS; sub-Saharan Africa; Retention in Care; Youth

### Introduction

In 2013, 4 million youth age 15–24 years were living with HIV and 85% of HIV-infected youth live in sub-Saharan Africa<sup>1</sup>, where AIDS is the number-one cause of death of adolescents<sup>2</sup>. The magnitude of the HIV epidemic among youth in sub-Saharan Africa is expected to increase as demographic projections predict a “youth bulge”, increasing the population at risk for new infections, and leading to a doubling of the 15–24 year old HIV-infected cohort in sub-Saharan Africa by 2020<sup>3</sup>. Retention in HIV care among this age group

---

**Corresponding Author:** Lillian B Brown, M.D., Ph.D., University of California, San Francisco, Division of HIV, Infectious Diseases, and Global Medicine, San Francisco General Hospital, 995 Potrero Ave, Building 80, Ward 84, San Francisco, CA 94110, Phone: 415-476-4082 x122, Fax: 415-476-6953, lillian.brown@ucsf.edu.

### Conflicts of interest:

VJ has received grant support from Gilead Sciences. DVH has received non-financial support from Gilead Sciences. CRC has received grants from the Bill & Melinda Gates Foundation, grants from CIFF, personal fees for legal consulting about a malpractice case, and personal fees from Symbiomix. All other authors have no other conflicts of interest to disclose.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

is essential to maximizing the benefits of antiretroviral therapy (ART), including improved quality of life, greater life expectancy, and prevention of new infections.

Prior to guidelines for universal treatment, HIV-infected youth who started ART were more likely to be lost to follow-up<sup>4–6</sup>, report lower adherence<sup>4,6</sup>, and were more likely to have detectable viral loads than older age groups<sup>4,5,7</sup>. After two years of universal HIV testing and treatment in rural east Africa as part of the Sustainable East Africa Research in Community Health (SEARCH) trial, 82% of all adults with HIV in intervention communities were virally suppressed compared to only 67% of those age 15–24<sup>8</sup>. These data suggest that even when high levels of viral suppression are achieved at the population level, current disparities could be exacerbated under universal treatment unless engagement in care among youth is specifically addressed.

Understanding factors associated with retention in care, including any unique predictors, among this vulnerable age group will help develop additional interventions. We describe predictors of 12-month retention in HIV care among youth (15–24 years) who are linking to HIV care for the first time in rural Kenya as part of the ongoing SEARCH universal test-and-treat trial and compare these to young adults (25–29 years) and older adults ( 30 years).

## Methods

SEARCH is a community cluster-randomized controlled trial (NCT01864683) in 12 pair-matched communities of approximately 10,000 persons each in rural Kenya and 20 pair-matched communities in rural Uganda. Each community underwent a census followed by population-wide HIV testing at baseline (June 2013 – June 2014) using a hybrid model that combined multi-disease community health campaigns with home-based testing for non-attendees<sup>9</sup>. In the intervention communities all HIV+ individuals were offered facilitated linkage to ART<sup>10</sup> delivered in a streamlined, patient-centered approach at quarterly visits<sup>11</sup>. Patients who missed a clinic visit received a tiered series of interventions to re-engage them in care, including a phone contact, home visit, and facilitated transport to return to clinic<sup>12,13</sup>.

This analysis includes all stable residents (>6 months/past year in the community) age 15 years in the six SEARCH intervention communities in Kenya who linked to care for the first time following baseline HIV testing. Those who linked to HIV care more than one year after testing or after database closure (September 16, 2015) are excluded from this analysis.

Retention in care was defined as not more than 90 days late to a scheduled follow-up visit. Patients were considered out of care (non-retention) if they were found alive, in the community and not enrolled in HIV care, were reported moved out of the community without a documented transfer to other care facility, or were lost to follow-up.

Demographics were obtained during the baseline year. Age was stratified into three categories: 15–24, 25–29, and 30 years. Retention was homogenous within these categories and did not violate the proportional hazards assumption as assessed graphically and with Schoenfeld residuals. All analyses were stratified by age category in order to evaluate age-specific predictors of retention.

Baseline demographics were compared by age group using chi-square test. Time-to-event analysis was performed for the primary outcome retention in care at 12 months in order to capture time in care for each individual. Patients entered the risk group ( $T_0$ ) at their first clinic visit after baseline HIV testing. Time to non-retention was calculated as the time between  $T_0$  and a patient's last scheduled clinic visit. Kaplan-Meier survival estimates were used to calculate probability of retention at one year. Hazard ratios for retention were computed using Cox proportional hazards modeling. Patients who had a documented transfer or died were censored. Follow-up continued until non-retention, censoring due to death or transfer, or 365 days after linkage. All models used robust standard errors and included community as a fixed-effect to control for clustering by community<sup>14</sup>. It was determined *a priori* to include gender in multivariate analysis due to significant gender imbalance across age strata, and to adjust for any variables that were significant at  $p<0.10$  in univariate analysis. Stata v14 (College Station, Texas) was used for analysis.

Ethical review boards of Makerere University, Uganda National Council of Science and Technology (Kampala, Uganda), Kenya Medical Research Institute (Nairobi, Kenya), and University of California, San Francisco (USA) approved this study. Participants provided consent for study participation.

## Results

Seven hundred sixty HIV-infected persons age 15 years linked to care following baseline HIV testing in the six intervention communities in Kenya. Of those who linked to care, 124 (16%) were age 15–24, 157 (21%) were age 25–29, and 479 (63%) were age 30 or older. A large majority of youth age 15–24 were female (89%) compared to older age groups (72% among age 25–29 and 53% among age 30,  $p<0.001$ ). Youth were also more likely to have an HIV-infected household member (36%, vs. 27% among 25–29 and 17% among 30,  $p<0.001$ ). No differences were observed by age group in the proportion married ( $p=0.26$ ), with access to a mobile phone ( $p=0.20$ ), pre-ART CD4+ count above country treatment guidelines ( $p=0.11$ ), or community health campaign vs. home-based HIV testing ( $p=0.49$ ) [Table].

Overall retention at one year was 94% (95% CI 91–96%) among adults 30, 90% (95% CI 84–94%) among young adults 25–29, and 81% (95% CI 73–88%) among youth 15–24 years. Having an HIV-infected household member was associated with increased retention (aHR 2.94; 95% CI 1.35–6.25) among age 15–24, with one-year retention of 90% (95% CI 77–96%) in this subgroup. Among the 44 HIV-infected household members of the 15–24 year olds, 32 were spouses, 3 were siblings, and 9 were parents. One-year retention was 77% (95% CI 65–85%) among the 80 youth without an HIV-infected household member.

Retention was not associated with education, marital status, time to link to care, or mobile phone access in any age group. Among 25–29 year olds, unemployment was associated with decreased retention (aHR 0.13; 95% CI 0.04–0.45). Among those 30 years, those who started ART with CD4+ count above country treatment guidelines (aHR 4.2; 95% CI 1.6–11.1) and those who tested through home-based testing (aHR 3.2; 1.2–10.0) had increased retention [Table].

## Discussion

Within Kenyan communities experiencing roll-out and scale-up of a universal HIV test-and-treat strategy, we found substantially lower rates of retention in care among the youth population, age 15–24 (81%, compared to 90–94% for persons age 25). We also found, however, that among youth, the presence of another HIV-infected household member substantially improved retention in care, indicating that youths may need and may benefit from augmented social support of family members in achieving durable success in HIV care.

Previous data from sub-Saharan Africa suggest an important role for social support among youth receiving HIV care. In an evaluation using routinely collected patient data from 160 HIV clinics in Kenya, Mozambique, Tanzania, and Rwanda attrition among youth who initiated ART was lower in clinics offering adolescent support groups<sup>15</sup>. An HIV support group and good parental supervision/monitoring were associated with lower non-adherence among adolescents in South Africa<sup>16,17</sup>. Women from multiple resource-limited settings in sub-Saharan Africa and Asia were less likely to be lost to follow up from pre-ART care if they co-enrolled with another adult household member, the majority of whom were spouses<sup>18</sup>. Youth age 15–21 in Kenya reported familial support, including financial and emotional support, facilitated retention in care<sup>19</sup>. We are continuing to analyze qualitative data to understand whether the higher retention observed among youth in our study who shared a household with another HIV-infected individual may reflect decreased stigma, increased support for clinic attendance, mechanisms for improved ART adherence, or a combination of these or other factors.

This analysis is limited to six communities in rural Kenya so these findings may not apply to other SEARCH intervention communities in Uganda or urban settings. Follow-up is limited to one year, however data suggests that most lost to follow-up occurs during the first year after ART initiation<sup>20</sup>. Finally, we do not have data on disclosure of HIV status, which could provide important context to social support provided by HIV-infected household members.

It is crucial to understand the obstacles to retention in HIV care youth face, and to implement tailored interventions to improve their outcomes at every stage of the HIV care cascade. Investigation of additional interventions that function to increase social support, such as peer navigation<sup>21,22</sup> and those leveraging the existing social networks of youth are urgently needed. Understanding the role that social support plays will provide important insight into how these social connections can be employed to improve engagement in care.

## Acknowledgments

### Sources of support:

Research reported in this manuscript was supported by the National Institutes of Mental Health of the U.S. Public Health Service grant T32 MH19105 and the Division of AIDS, National Institute of Allergy and Infectious Diseases of the National Institutes of Health award number U01AI099959 and Gilead Sciences. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or Gilead.

## References

1. UNAIDS. Global Report: UNAIDS Report on the Global AIDS Epidemic 2013. Geneva, Switzerland: UNAIDS; 2013.
2. UNICEF. Annual Report 2015. New York, NY: United Nations Children's Fund; 2016.
3. Bank W. World Bank Development Report 2007: Development and the Next Generation. Washington, DC: World Bank; 2007.
4. Nachege JB, Hislop M, Nguyen H, et al. Antiretroviral therapy adherence, virologic and immunologic outcomes in adolescents compared with adults in southern Africa. *Journal of acquired immune deficiency syndromes* (1999). 2009; 51(1):65–71. [PubMed: 19282780]
5. Evans D, Menezes C, Mahomed K, et al. Treatment outcomes of HIV-infected adolescents attending public-sector HIV clinics across Gauteng and Mpumalanga, South Africa. *AIDS research and human retroviruses*. 2013; 29(6):892–900. [PubMed: 23373540]
6. Vinikoor MJ, Joseph J, Mwale J, et al. Age at antiretroviral therapy initiation predicts immune recovery, death, and loss to follow-up among HIV-infected adults in urban Zambia. *AIDS research and human retroviruses*. 2014; 30(10):949–955. [PubMed: 24998881]
7. Jobanputra K, Parker LA, Azih C, et al. Factors associated with virological failure and suppression after enhanced adherence counselling, in children, adolescents and adults on antiretroviral therapy for HIV in Swaziland. *PloS one*. 2015; 10(2):e0116144. [PubMed: 25695494]
8. Petersen, MBL., Kwarisiima, D., Sang, N., Chamie, G., Ayieko, J., Kabami, J., Owaraganise, A., Liegler, T., Mwangwa, F., Kadede, K., Jain, V., Plenty, A., Lavoy, G., Black, D., Bukusi, E., Cohen, C., Clark, T., Charlebois, E., Kamya, M., Havlir, D. SEARCH test and treat study in Uganda and Kenya exceeds the UNAIDS 90-90-90 cascade target by achieving 81% population-level viral suppression after 2 years. Paper presented at: AIDS 20162016; Durban, South Africa.
9. Chamie G, Clark TD, Kabami J, et al. A hybrid mobile approach for population-wide HIV testing in rural east Africa: an observational study. *The lancet HIV*. 2016; 3(3):e111–119. [PubMed: 26939734]
10. Ayieko, JVRA., Owaraganise, A., Mwangwa, F., Jain, V., Brown, L., Ruel, T., Clark, T., Black, D., Exarchos, A., Kwarisiima, D., Bukusi, EA., Cohen, CR., Kamya, M., Geng, E., Petersen, M., Havlir, D., Charlebois, E. A novel strategy for accelerated linkage to care following community-wide HIV testing. Paper presented at: International AIDS Conference2016; Durban, South Africa.
11. Kwarisiima, DJV., Owaraganise, A., Mwangwa, F., Byonanebye, D., Ayieko, J., Petersen, M., Havlir, DV., Kamya, MR. Virologic Efficacy of ART Begun at High CD4+ Counts via Streamlined Care in East Africa. Paper presented at: Conference on Retroviruses and Opportunistic Infections2016; Boston, MA.
12. Brown LB, Havlir DV, Ayieko J, et al. High levels of retention in care with streamlined care and universal test and treat in East Africa. *AIDS (London, England)*. 2016; 30(18):2855–2864.
13. Jain V, Byonanebye DM, Amanyire G, et al. Successful antiretroviral therapy delivery and retention in care among asymptomatic individuals with high CD4+ T-cell counts above 350 cells/mul in rural Uganda. *AIDS (London, England)*. 2014; 28(15):2241–2249.
14. Dieleman JL, Templin T. Random-effects, fixed-effects and the within-between specification for clustered data in observational health studies: a simulation study. *PloS one*. 2014; 9(10):e110257. [PubMed: 25343620]
15. Lamb MR, Fayorsey R, Nuwagaba-Biribonwoha H, et al. High attrition before and after ART initiation among youth (15–24 years of age) enrolled in HIV care. *AIDS (London, England)*. 2014; 28(4):559–568.
16. Cluver LD, Orkin FM, Boyes ME, Sherr L. Cash plus care: social protection cumulatively mitigates HIV-risk behaviour among adolescents in South Africa. *AIDS (London, England)*. 2014; 28(Suppl 3):S389–397.
17. Cluver LD, Toska E, Orkin FM, et al. Achieving equity in HIV-treatment outcomes: can social protection improve adolescent ART-adherence in South Africa? *AIDS care*. 2016; 28(Suppl 2):73–82. [PubMed: 27392002]
18. Gwynn RC, Fawzy A, Viho I, Wu Y, Abrams EJ, Nash D. Risk factors for loss to follow-up prior to ART initiation among patients enrolling in HIV care with CD4+ cell count  $\geq 200$  cells/muL in

the multi-country MTCT-Plus Initiative. *BMC health services research*. 2015; 15:247. [PubMed: 26108273]

19. Wolf HT, Halpern-Felsher BL, Bukusi EA, Agot KE, Cohen CR, Auerswald CL. "It is all about the fear of being discriminated [against]...the person suffering from HIV will not be accepted": a qualitative study exploring the reasons for loss to follow-up among HIV-positive youth in Kisumu, Kenya. *BMC public health*. 2014; 14:1154. [PubMed: 25377362]
20. Fox MP, Rosen S. Retention of Adult Patients on Antiretroviral Therapy in Low- and Middle-Income Countries: Systematic Review and Meta-analysis 2008–2013. *Journal of acquired immune deficiency syndromes (1999)*. 2015; 69(1):98–108. [PubMed: 25942461]
21. Lippman SA, Shade SB, Sumitani J, et al. Evaluation of short message service and peer navigation to improve engagement in HIV care in South Africa: study protocol for a three-arm cluster randomized controlled trial. *Trials*. 2016; 17:68. [PubMed: 26852237]
22. Graham SM, Micheni M, Kombo B, et al. Development and pilot testing of an intervention to promote care engagement and adherence among HIV-positive Kenyan MSM. *AIDS (London, England)*. 2015; 29(Suppl 3):S241–249.

Table

Retention by age category among all adults linking to care for the first time after baseline HIV testing in SEARCH intervention communities

	<u>Age 15 – 24 years (N = 124)</u>			<u>Age 25 – 29 years (N = 157)</u>			<u>Age 30 years (N = 479)</u>		
	n (%)	HR (95% CI)	aHR (95% CI)	n (%)	HR (95% CI)	aHR (95% CI)	n (%)	HR (95% CI)	aHR (95% CI)
<b>Sex</b>									
Male	14 (11%)	1.0	1.0	44 (28%)	1.0	1.0	226 (47%)	1.0	1.0
Female	110 (89%)	0.88 (0.18 – 4.34)	0.56 (0.12 – 2.44)	113 (72%)	2.22 (0.83 – 6.25)	2.63 (0.86 – 8.33)	253 (53%)	1.09 (0.52 – 2.27)	1.19 (0.54 – 2.63)
<b>Education</b>									
Primary	118 (95%)	1.0		147 (93%)	1.0		433 (90%)	1.0	
Any secondary or greater	6 (5%)	0.35 (0.11 – 1.12)		10 (6%)	0.44 (0.09 – 2.13)		46 (10%)	3.33 (0.45 – 25.0)	
<b>Occupation</b>									
Employed	97 (78%)	1.0		148 (93%)	1.0	1.0	453 (95%)	1.0	
Student or unemployed	27 (22%)	0.76 (0.27 – 2.22)		11 (7%)	0.14 (0.04 – 0.45)	0.13 (0.04 – 0.45)	23 (5%)	0.98 (0.64 – 1.83)	
<b>Marital Status</b>									
Married	96 (77%)	1.0		131 (83%)	1.0		345 (72%)	1.0	
Unmarried	28 (23%)	1.01 (0.35 – 2.94)		26 (17%)	0.15 (0.05 – 0.44)		134 (28%)	0.77 (0.34 – 1.72)	
<b>Other household member HIV</b>									
+									
No/Unknown	80 (65%)	1.0	1.0	114 (73%)	1.0		396 (83%)	1.0	
Yes	44 (36%)	2.70 (1.15 – 6.25)	2.94 (1.35 – 6.25)	43 (27%)	1.04 (0.36 – 3.13)		83 (17%)	0.75 (0.31 – 1.82)	
<b>Pre-ART CD4</b>									
<350 cells/mm <sup>3</sup>	60 (48%)	1.0		69 (44%)	1.0		255 (53%)	1.0	1.0
350 cells/mm <sup>3</sup>	64 (52%)	1.81 (0.74 – 4.35)		88 (54%)	1.72 (0.60 – 5.00)		224 (47%)	4.34 (1.59 – 12.5)	4.17 (1.56 – 11.1)
<b>Testing Location</b>									
CHC	81 (65%)	1.0		94 (60%)	1.0		285 (60%)	1.0	1.0
HBT	43 (35%)	1.56 (0.61 – 4.00)		63 (40%)	0.82 (0.28 – 2.44)		194 (40%)	3.23 (1.23 – 8.33)	3.23 (1.22 – 10.0)
<b>Time to link</b>									
< 30 days	68 (55%)	1.0		95 (60%)	1.0		279 (58%)	1.0	
30 days	56 (45%)	0.52 (0.21 – 1.27)		62 (40%)	0.57 (0.20 – 1.64)		200 (42%)	0.51 (0.22 – 1.20)	
<b>Access to mobile phone</b>									
Yes	77 (62%)	1.0		112 (71%)	1.0		333 (70%)	1.0	
No	47 (38%)	0.74 (0.30 – 1.82)		45 (29%)	0.60 (0.22 – 1.64)		146 (30%)	0.68 (0.30 – 1.52)	